Please login to the form below

Not currently logged in
Email:
Password:

Cerezyme

This page shows the latest Cerezyme news and features for those working in and with pharma, biotech and healthcare.

Sanofi rare disease drug a breakthrough, says FDA

Sanofi rare disease drug a breakthrough, says FDA

Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Patients with Gaucher disease are currently started on injectable therapy with enzyme replacement drugs such as Genzyme's own Cerezyme (imiglucerase), the top-selling medicine for the rare disease with sales ... Analysts have suggested Cerdelga could

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    be treated with intravenous injections such as enzyme replacement treatment Cerezyme (imiglucerase), also made by Genzyme. ... Cerdelga has demonstrated it is as effective as Cerezyme in clinical trials and was approved in the US in August.

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen. ... The company said it wants a pricing strategy that does not drive patients towards either Cerezyme or Cerdelga, making the choice of therapy a purely clinical

  • EMA publishes European drug shortage details EMA publishes European drug shortage details

    First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... Drugs featured in the first version of the shortages catalogue include Sanofi/Genzyme's Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta), which are approved

  • Sanofi predicts return to growth in second half Sanofi predicts return to growth in second half

    Genzyme's portfolio of rare disease therapies increased more than a quarter to 493m as restricted supplies of Gaucher disease therapy Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) for Fabry disease caused ... Cerezyme grew 17 per cent to 171m,

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...